ProQR Therapeutics
PRQR
62 hedge funds and large institutions have $82.4M invested in ProQR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 7 closing their positions.
650% more call options, than puts
Call options by funds: $150K | Put options by funds: $20K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more capital invested
Capital invested by funds: $54.9M → $82.4M (+$27.5M)
0.8% less ownership
Funds ownership: 39.25% → 38.45% (-0.8%)
5% less funds holding
Funds holding: 65 → 62 (-3)
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.77M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.41M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$350K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$290K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.44M |
| 2 |
Millennium Management
New York
|
-$1.24M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.05M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$715K |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$164K |
PRQR Hedge Fund Activity: Q2 2025 in Review
62 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2025, worth a combined $82.4M — up 50% from $54.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PRQR and 4 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 17 added.
The largest buyer was Morgan Stanley, adding an estimated $2.77M. The largest seller was Adage Capital Partners, cutting an estimated $2.44M.
- 62 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2025, down from 65 in Q1 2025.
- Funds reported $82.4M of ProQR Therapeutics stock for Q2 2025, up 50% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q2 2025 and 7 closed out, a net change of -3 holders.
- The largest ProQR Therapeutics buyer in Q2 2025 was Morgan Stanley, an estimated $2.77M added.
- The largest ProQR Therapeutics seller in Q2 2025 was Adage Capital Partners, an estimated $2.44M sold.
Based on aggregated 13F filings for Q2 2025.